Classical PKC isoforms in cancer

被引:120
作者
Martiny-Baron, Georg [1 ]
Fabbro, Doriano [1 ]
机构
[1] Novartis Inst Bomed Res, Expertise Platform Kinases, CH-4002 Basel, Switzerland
关键词
protein kinase C; PKC inhibitors; cancer;
D O I
10.1016/j.phrs.2007.04.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Protein kinases C (PKCs) are a family of serine/threonine kinases which are involved in tumor formation and progression. Although PKC over-expression has been shown to contribute to cell transformation, PKCs are not considered to be classical oncogenes which are activated by mutations, but considered as tumor promoters that enhance multiple cellular signaling pathways. Over the last two decades a lot of evidence has emerged demonstrating a role for various PKC isoforms in cancer. Small molecular weight inhibitors and antisense molecules have been developed, specifically targeting the calcium dependent classical isoforms of PKC. This review focuses on the role of classical PKCs in cancer and the results obtained by attempting to inhibit these enzymes to achieve a therapeutic benefit. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:477 / 486
页数:10
相关论文
共 154 条
[51]   Activation mutations of human c-KIT resistant to imatinib, mesylate are sensitive to the tyrosine kinase inhibitor PKC412 [J].
Growney, JD ;
Clark, JJ ;
Adelsperger, J ;
Stone, R ;
Fabbro, D ;
Griffin, JD ;
Gilliland, DG .
BLOOD, 2005, 106 (02) :721-724
[52]   DIFFERENTIAL INHIBITION BY STAUROSPORINE OF PHORBOL ESTER, BRYOSTATIN AND OKADAIC ACID EFFECTS ON MOUSE SKIN [J].
GSCHWENDT, M ;
KITTSTEIN, W ;
LINDNER, D ;
MARKS, F .
CANCER LETTERS, 1992, 66 (02) :139-146
[53]   The role of protein kinase C-alpha (PKC-α) in cancer and its modulation by the novel PWC-α-specific inhibitor aprinocarsen [J].
Hanauske, AR ;
Sundell, K ;
Lahn, M .
CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (16) :1923-1936
[54]   Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain [J].
Heidel, F ;
Solem, FK ;
Breitenbuecher, F ;
Lipka, DB ;
Kasper, S ;
Thiede, MH ;
Brandts, C ;
Serve, H ;
Roesel, J ;
Giles, F ;
Feldman, E ;
Ehninger, G ;
Schiller, GJ ;
Nimer, S ;
Stone, RM ;
Wang, YF ;
Kindler, T ;
Cohen, PS ;
Huber, C ;
Fischer, T .
BLOOD, 2006, 107 (01) :293-300
[55]  
HOCEVAR BA, 1991, J BIOL CHEM, V266, P28
[56]   Modulation of protein kinase C in antitumor treatment [J].
Hofmann, J .
REVIEWS OF PHYSIOLOGY BIOCHEMISTRY AND PHARMACOLOGY, 2001, 142 :1-96
[57]  
Hsueh CT, 1998, CLIN CANCER RES, V4, P2201
[58]  
HUGAND H, 1993, BIOCHEM J, V291, P329
[59]   Regulation of volume-activated chloride channels by P-glycoprotein: phosphorylation has the final say! [J].
Idriss, HT ;
Hannun, YA ;
Boulpaep, E ;
Basavappa, S .
JOURNAL OF PHYSIOLOGY-LONDON, 2000, 524 (03) :629-636
[60]   Antisense therapy for cancer - the time of truth [J].
Jansen, B ;
Zangemeister-Wittke, U .
LANCET ONCOLOGY, 2002, 3 (11) :672-683